Shorts

1:15
Evolving Landscape of Myasthenia Gravis Treatment
a year ago
by
Leila Darki, MD(+1 more)

1:05
Aerobic Exercise and Promoting Remyelination in MS
a year ago
by
Lindsey Wooliscroft, MD, MS(+1 more)

1:12
MDS 2025: Learning From Progress in Other Disease States
a year ago
by
Lorraine Kalia, MD, PhD(+1 more)

1:16
MDS 2025: Biologically Defining Parkinson Disease
a year ago
by
Tanya Simuni, MD, FAAN(+1 more)

1:32
MDS 2025: Environmental Exposures and PD
a year ago
by
Web Ross, MD(+1 more)

0:53
MDS 2025: Novel Therapeutics and Biomarkers for PD
a year ago
by
Veronica Santini, MD, MA(+1 more)

0:38
MDS 2025: PD and the Gut Microbiome
a year ago
by
Samia Ben Sassi, MD(+1 more)

1:49
MDS 2025: Parkinson Disease and Brain Organization
a year ago
by
A. Jon Stoessl, CM, MD(+1 more)

0:53
MDS 2025: Exercise and Diet's Impact on Parkinson Disease
a year ago
by
Jonas Hannestad, MD, PhD(+1 more)

1:21
Migraine Care Needs of the LGBTQIA+ Patient Population
a year ago
by
Anna Pace, MD(+1 more)

1:16
Impact of Speech and Physical Therapy in Parkinson Disease
a year ago
by
Cynthia Fox, PhD, CCC-SLP(+1 more)

1:33
Biomarkers to Guide Remyelination Strategies in MS
a year ago
by
Ahmed Abdelhak, MD(+1 more)

1:07
Early Identification of Atypical Parkinsonian Syndromes
a year ago
by
David Shprecher, DO, MSci, FAAN(+1 more)

1:28
Subjective Cognitive Complaints During the Interictal Period in Migraine
a year ago
by
Laura Sebrow, PhD(+1 more)

1:10
Consensus Definitions for Refractory and Resistant Migraine
a year ago
by
Jennifer Robblee, MD(+1 more)

1:10
The Future of Migraine Treatment
a year ago
by
Patricia Pozo-Rosich, MD, PhD(+1 more)

1:10
Understanding Adolescent Migraine Suffering
a year ago
by
Patricia Pozo-Rosich, MD, PhD(+1 more)

0:30
Overviewing New Gene Therapy Guidelines w/ Dr. Byrne
a year ago
by
Marco Meglio(+1 more)

1:00
Multidisciplinary Care for Gene Therapy Use in DMD
a year ago
by
Marco Meglio(+1 more)
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Early Data Show Dual-Targeting CAR-T Agent CTA313 Stabilizes Progressive Multiple Sclerosis
2
Clene Submits NDA Seeking Accelerated Approval for ALS Drug
3
CAR-T Agent Zola-cel Shows No New Multiple Sclerosis Disease Activity in Phase 1 Study
4
CALLIPER Extension Data Show Sustained Disability Outcomes With Vidofludimus Calcium in Progressive MS
5
